DGAP-News: SuppreMol GmbH: SuppreMol begins development of Anti-IL-3 monoclonal antibody to diagnose and treat early stage Rheumatoid Arthritis
(firmenpresse) - DGAP-News: SuppreMol GmbH / Key word(s): Study
SuppreMol GmbH: SuppreMol begins development of Anti-IL-3 monoclonal
antibody to diagnose and treat early stage Rheumatoid Arthritis
24.07.2012 / 10:25
---------------------------------------------------------------------
Press Release
SuppreMol begins development of Anti-IL-3 monoclonal antibody to diagnose
and treat early stage Rheumatoid Arthritis
- Licensing Agreement with the University Hospital of Regensburg
- EUR 1.37 million grant from the m4 Personalized Medicine Initiative
Munich, Germany, 24th July, 2012: SuppreMol GmbH, an autoimmune disease
specialist, today announced a licensing agreement with the University
Hospital of Regensburg to develop SM401, a humanized anti-IL-3 monoclonal
antibody for early diagnosis and treatment of Rheumatoid Arthritis (RA).
SuppreMol will advance preclinical development of SM401 for treatment of
RA. Simultaneously, the Company will further validate a highly sensitive
human IL-3 diagnostic assay for patient stratification.
SuppreMol's preclinical candidate SM401 has demonstrated, in a murine model
for RA, that it significantly reduces progression and severity of the
disease. At the same time, levels of the inflammatory cytokines IL-6 and
TNF-alpha, which are reduced by several established RA drugs, are also
lowered. Furthermore, it has been demonstrated that IL-3 concentrations
were only elevated at the onset of arthritis and fell to low levels during
the course of the disease in the animal model. Using the newly developed
IL-3 diagnostic assay, SuppreMol expects to develop a biomarker for the
stratification of RA patients.
'This SM401 program advances SuppreMol's strategy to target very early
events in the development of autoimmune diseases,' said Dr. Peter
Sondermann, CSO and co-founder of SuppreMol GmbH. 'Through this early
intervention approach we expect to stop progression of the autoimmune
disease rather than simply treating symptoms of inflammation. We expect to
begin clinical trials in 2014.'
The anti-IL-3 monoclonal antibody was generated by the group of Professor
Dr. Matthias Mack at Regensburg University Hospital - Internal Medicine II,
following the discovery that increased levels of IL-3 indicate early onset
and activity of RA. Prof. Mack is a member of SuppreMol's Scientific
Advisory Board.
'This licensing agreement with Bayerische Patentallianz GmbH provides
SuppreMol a very strong portfolio of autoimmune therapies and a potential
companion RA diagnostic,' said Professor Dr. Peter Buckel, CEO of SuppreMol
GmbH. 'Along with our Fc gamma receptor platform with three clinical and
two further preclinical programs targeting autoimmune diseases and
allergies, this SM401 program is another building block in the strong
foundation of the company's future,' he added. Bayerische Patentallianz
GmbH is the central patent and marketing agency of the Bavarian
Universities and Universities of Applied Sciences, including the University
of Regensburg.
Early development of SM401 is being funded by a grant of EUR 1.37 million
from the German Federal Ministry of Education and Research (BMBF). The
project was funded in Prof. Mack's laboratory through BayImmuNet, the
Bayerisches Immuntherapie Netzwerk; the development of a therapeutic
anti-IL-3 antibody including a highly sensitive IL-3 assay is supported by
the German Federal Ministry of Education and Research within the
Leading-Egde Cluster 'm4 - Personalized Medicine and Targeted Therapies' in
Munich.
About SuppreMol
SuppreMol, a privately held biopharmaceutical company, is developing novel
proteins to treat autoimmune diseases. The company is pioneering the
development of soluble Fc gamma receptors (Fc(Rs), which are recombinant
autologous therapeutic proteins with a specific immunoregulatory potential.
Currently, the company is developing Fc(Rs for the treatment of Primary
Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) in
Phase II clinical trials. Further building its platform of selective
immunoregulators, SuppreMol is working on antibody programs targeting Fc
receptors and other immunomodulatory molecules for alternative treatment
strategies in autoimmune conditions, including a humanized anti-IL-3
monoclonal antibody for early diagnosis and treatment of Rheumatoid
Arthritis (RA). SuppreMol was founded as a spin-off from the laboratory of
Prof. Dr. Robert Huber, Nobel Prize in Chemistry 1988, at the Max Planck
Institute for Biochemistry in Martinsried, Germany. To date SuppreMol has
raised EUR 35.8 million through private investors and EUR 11.7 million in
project funding. The last round in 2010 raised EUR 15.5 million in a Series
C financing. Investors in the company include MIG Fonds, BioMedPartners AG,
Santo Holding GmbH and FCP Biotech Holding GmbH along with KfW
Mittelstandsbank, Bayern Kapital GmbH, Max Planck Society, and Z-Cube.
Contact
SuppreMol GmbHEnd of Corporate News
Prof. Dr. Peter Buckel
Chief Executive Officer
Tel: +49 89 30 90 50 680
E-
mail: info(at)suppremol.com
www.suppremol.com
---------------------------------------------------------------------
24.07.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
178896 24.07.2012
Themen in dieser Pressemitteilung:
suppremol-gmbh-suppremol-begins-development-of-anti
il
3-monoclonal-antibody-to-diagnose-and-treat-early-stage-rheumatoid-arthritis
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: EquityStory
" alt="Golden Predator Receives Major Exploration Permit for Brewery Creek
Datum: 24.07.2012 - 10:25 Uhr
Sprache: Deutsch
News-ID 167851
Anzahl Zeichen: 6780
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 300 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: SuppreMol GmbH: SuppreMol begins development of Anti-IL-3 monoclonal antibody to diagnose and treat early stage Rheumatoid Arthritis"
steht unter der journalistisch-redaktionellen Verantwortung von
SuppreMol GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
